| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
| Web: | mayocliniclabs.com |
|---|---|
| Email: | mcl@mayo.edu |
| Telephone: | 800-533-1710 |
| International: | +1 855-379-3115 |
| Values are valid only on day of printing | |
Mayo Clinic Laboratories is leading an evolution in neurology testing. Propelled by ongoing discoveries of clinically relevant biomarkers, our laboratory scientists integrate research findings into test development and implementation. Collaboration between our labs and the clinical practice at Mayo Clinic supports development of clinically validated testing that delivers actionable answers for patients.
“The ability of Mayo Clinic to make discoveries and translate these into solutions for our patients is critical to our mission.”
John Mills, Ph.D., co-director, Neuroimmunology Laboratory
OUR DIFFERENCE
The latest
For many, the path to a correct diagnosis can be long and filled with uncertainty. This story highlights the resilience and determination of one patient who navigated a complex medical journey to find answers and hope at Mayo Clinic. The patient asked to remain anonymous for personal privacy reasons.
Mayo Clinic researchers report that spinal cord inflammation associated with an antibody to myelin oligodendrocyte glycoprotein can mimic acute flaccid myelitis, a rare but serious disease linked to certain viruses that particularly affects children and can result in paralysis.
Sean Pittock, M.D., and Andrew McKeon, M.B., B.Ch., M.D., were featured in a Post Bulletin series about autoimmune neurology disorders and the research and services that Mayo Clinic offers patients.
This week’s Research Roundup highlights the association of apolipoprotein E ε4 with transactive response DNA-binding protein 43.
For patients who have been diagnosed with acute disseminated encephalomyelitis, Mayo researchers have found a direct correlation between a specific antibody, myelin oligodendrocyte glycoprotein—also known as MOG, and an increased risk of recurring attacks in these individuals.
Necrotizing autoimmune myopathy (NAM) is a serious but rare muscle disease strongly associated with autoantibodies to either the protein signal recognition particle (SRP) or the enzyme 3-hydroxy-3-methylglutaryl-coenzyme A reductase (HMGCR). NAM typically manifests with subacute proximal limb muscle weakness and persistently elevated serum creatine kinase (CK) concentrations, but slower onsets can occur and complicate diagnosis.
This week’s Research Roundup highlights paraneoplastic neuronal intermediate filament autoimmunity.
In 2017, Mayo Clinic launched a first-in-the-U.S. clinical test to help patients with some autoimmune disorders get the right diagnosis faster. The test defines a new form of inflammatory demyelinating disease, called myelin oligodendrocyte glycoprotein autoimmunity, which is distinct from multiple sclerosis, with which it is commonly confused.
Andrew McKeon, M.D., M.B., B.Ch., and Sean J. Pittock, M.D., neurologists and co-directors of the Mayo Clinic Neuroimmunology Laboratory in Rochester, Minnesota, answer questions about Mayo Clinic's new test.
This week’s Research Roundup highlights potential genetic modifiers of disease risk and age at onset in patients with frontotemporal lobar degeneration and GRN mutations.
For people with encephalitis, rapid treatment of their acute brain inflammation is critical for avoiding devastating physical and cognitive deficits. But appropriate treatment requires identifying the culprit causing the symptoms.
Encephalitis caused by the immune system attacking the brain is similar in frequency to encephalitis from infections, Mayo Clinic researchers report in Annals of Neurology.
Life with an inherited disease sometimes brings unexpected twists and turns. Learn how five-year-old Gus Erickson has navigated the gyrations with the help of Mayo Clinic’s Neurofibromatosis Clinic.